BIND Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update

BIND Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update

May 7, 2015

-First Patient Dosed in Squamous Histology Cohort and Enrollment On-track in KRAS Mutant Cohort of iNSITE 1 Clinical Trial in NSCLC-

-Milestone Achieved in Collaboration with AstraZeneca and Second Accurin Candidate, AZD2811, Expected to Enter Clinic in 2H2015-

- Management to host conference call today at 8:30 a.m. EDT -

Agios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120

Agios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120

May 7, 2015
  • AG-221: Ongoing Phase 1 study expanded by an additional 125 patients in selected AML (acute myeloid leukemia) populations
  • AG-120: Ongoing Phase 1 hematologic malignancy study expanded by 175 patients in three cohorts, including 125 patients in a defined AML population
  • EHA: Abstracts for three lead clinical programs accepted for presentation at the 20th Congress of the European Hematology Association (EHA)

Acceleron Pharma Reports First Quarter 2015 Financial and Operational Results

Acceleron Pharma Reports First Quarter 2015 Financial and Operational Results

May 7, 2015

– Luspatercept phase 2 data showed encouraging activity in lower risk myelodysplastic syndromes (MDS) patients –

– Celgene and Acceleron selected luspatercept to advance into Phase 3 programs in MDS and beta-thalassemia by year-end –

– Promising data from dalantercept phase 2 clinical trial in patients with renal cell carcinoma presented at ASCO-GU conference – 

T2 Biosystems Reports 2015 First Quarter Results

T2 Biosystems Reports 2015 First Quarter Results

May 5, 2015

LEXINGTON, Mass., May 5, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems (Nasdaq:TTOO) today reported operating highlights and financial results for the first quarter ended March 31, 2015. Recent operational highlights included:

Eleven Biotherapeutics Presents Data on EBI-031 for the Treatment of Diabetic Macular Edema at ARVO 2015 Annual Meeting

Eleven Biotherapeutics Presents Data on EBI-031 for the Treatment of Diabetic Macular Edema at ARVO 2015 Annual Meeting

May 5, 2015

Preclinical Data on EBI-031 Demonstrates Potent IL-6 Inhibition and Extended Vitreal Retention

Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting

Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting

May 6, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced six abstracts have been accepted for one oral and five poster presentations at the 18th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The presentations will detail data from research programs across a broad range of disease areas, including cancer, hematologic (blood) and ophthalmic (eye) diseases. The meeting will take place May 13-16 at the Hyatt Regency in New Orleans. Following is a schedule of Editas’ poster and oral presentations:

Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestlé Health Science and Bayer CropScience

Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestlé Health Science and Bayer CropScience

May 5, 2015

Scaling Entrepreneurial Innovations in Life Sciences

Syros Pharmaceuticals Augments Senior Leadership Team

Syros Pharmaceuticals Augments Senior Leadership Team

April 30, 2015

Adds significant depth to chemistry, corporate development and finance functions

WATERTOWN, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, today announced the addition of three senior members to the company. Jonathan Garen joins the Company as Chief Business Officer; Christopher Roberts, Ph.D., as Vice President of Chemistry and Early Development; and Colleen DeSimone as Vice President of Finance and Controller.

Eleven Biotherapeutics Reports First Quarter 2015 Financial Results

Eleven Biotherapeutics Reports First Quarter 2015 Financial Results

April 30, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the first quarter ended March 31, 2015, and recent business highlights.

Celgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic Syndromes

Celgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic Syndromes

April 30, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that Acceleron and its collaboration partner, Celgene Corporation, plan to initiate a Phase 3 program with luspatercept in myelodysplastic syndromes and beta-thalassemia by year-end 2015. The companies will continue to develop sotatercept for patients with chronic kidney disease.